AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Alvotech (ALVO)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

12.53

-0.46 (-3.54%)

At close: Feb 18, 2025, 3:59 PM

12.58

0.44%

After-hours: Feb 18, 2025, 04:00 PM EST

undefined% (undefined)

Bid	12.14
Market Cap	3.78B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.85
PE Ratio (ttm)	-6.77
Forward PE	n/a
Analyst	Buy

Ask	12.58
Volume	164,278
Avg. Volume (20D)	150,840
Open	12.83
Previous Close	12.99
Day's Range	12.50 - 12.89
52-Week Range	9.15 - 18.00
Beta	undefined

About ALVO

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date Jun 16, 2022

Employees 999

Stock Exchange NASDAQ

Ticker Symbol ALVO

Website https://www.alvotech.com

Full Company Profile

Analyst Forecast

According to 1 analyst ratings, the average rating for ALVO stock is "Buy." The 12-month stock price forecast is $18, which is an increase of 43.71% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Alvotech is scheduled to release its earnings on Mar 19, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 months ago

-1.89%

Alvotech shares are trading higher after the compa... Unlock content with Pro Subscription

6 months ago

-3.47%

Alvotech shares are trading lower after the company announced an offering of up to 1,789,087 shares by the selling shareholder.

News

20 hours ago · investopedia.com

FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea

Teva Pharmaceutical Industries (TEVA) and partner Alvotech (ALVO) said the Food and Drug Administration (FDA) agreed to review their AVTO6 treatment for eye disorders.

1 month ago · zacks.com

Has Alvotech (ALVO) Outpaced Other Medical Stocks This Year?

Here is how Alvotech (ALVO) and Becton Dickinson (BDX) have performed compared to their sector so far this year.

1 month ago · zacks.com

Are Medical Stocks Lagging Alvotech (ALVO) This Year?

Here is how Alvotech (ALVO) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

2 months ago · zacks.com

Wall Street Analysts Believe Alvotech (ALVO) Could Rally 39.83%: Here's is How to Trade

The mean of analysts' price targets for Alvotech (ALVO) points to a 39.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst...

2 months ago · zacks.com

Is Alvotech (ALVO) Stock Outpacing Its Medical Peers This Year?

Here is how Alvotech (ALVO) and Twist Bioscience (TWST) have performed compared to their sector so far this year.

3 months ago · seekingalpha.com

Alvotech's Position In The Coming Biosimilar Gold Rush

Alvotech focuses on biosimilars, aiming to lower healthcare costs amid rising drug prices and regulatory pressure against price hikes. Alvotech's aggressive market expansion shows promise with signifi...